Inactive Instrument

Alder BioPharmaceuticals, Inc.

Equities

US0143391052

Biotechnology & Medical Research

Alder BioPharmaceuticals® to Present at 38th Annual Cowen & Co. Health Care Conference

March 05, 2018 at 04:06 pm EST

BOTHELL, Wash., March 05, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will webcast a business overview and update by Mark J. Litton, Ph.D., MBA, chief business officer, at the 38^th Annual Cowen & Co. Health Care Conference at 4:50 p.m. ET on Monday, March 12, 2018 in Boston, MA.

A live audio webcast of the event can be accessed on the Events & Presentations page of the Investors section of Alder's website at http://www.alderbio.com, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder's website for at least 30 days after the live event concludes.

Link: http://wsw.com/webcast/cowen46/aldr/

About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company committed to transforming the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions. Leveraging its pioneering monoclonal antibody technologies, Alder discovers and develops novel therapeutic antibodies designed to deliver highly differentiated, best-in-class clinical profiles. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated as potentially the first-to-market migraine prevention infusion therapy. Eptinezumab is a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide (CGRP), which is believed to play a key role in mediating and initiating migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.

Media Contact:
Ashley Cadle
TogoRun
310-463-0143
a.cadle@togorun.com

Investor Relations Contact:
Michael Schaffzin
Stern Investor Relations, Inc.
212-362-1200
michael@sternir.com

Latest news about Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals, Inc. Announces Board Changes	19-10-22	CI
Alder BioPharmaceuticals, Inc.(NasdaqGM:ALDR) dropped from S&P Biotechnology Select Industry Index	19-10-22	CI
Alder BioPharmaceuticals, Inc.(NasdaqGM:ALDR) dropped from S&P Global BMI Index	19-10-22	CI
Alder BioPharmaceuticals, Inc.(NasdaqGM:ALDR) dropped from S&P TMI Index	19-10-22	CI
H. Lundbeck A/S completed the acquisition of Alder BioPharmaceuticals, Inc..	19-10-21	CI
Alder BioPharmaceuticals, Inc. Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of Migraine	19-10-10	CI
H Lundbeck : Lundbeck buys Alder in $2 billion migraine treatment move	19-09-16	RE
H. Lundbeck A/S signed a Letter of Intent to acquire Alder BioPharmaceuticals, Inc. for $1.5 billion.	19-09-15	CI
Transcript : Alder BioPharmaceuticals, Inc. Presents at Morgan Stanley 17th Annual Global Healthcare Conference, Sep-10-2019 02:55 PM	19-09-10
Transcript : Alder BioPharmaceuticals, Inc., Q2 2019 Earnings Call, Aug 06, 2019	19-08-06
Alder Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-06	CI
Alder BioPharmaceuticals, Inc. Presents New Data on Migraine-Free Months, Migraine Severity and Quality of Life, Demonstrating Eptinezumab’s Clinical Profile for Migraine Prevention	19-07-11	CI
Alder BioPharmaceuticals® to Showcase 14 New Data Presentations Demonstrating Eptinezumab’s Migraine Prevention and Quality of Life Impact at American Headache Society Meeting	19-07-08	CI
Transcript : Alder BioPharmaceuticals, Inc. - Analyst/Investor Day	19-06-26
Transcript : Alder BioPharmaceuticals, Inc. Presents at UBS Global Healthcare Conference 2019, May-22-2019 10:00 AM	19-05-22
Alder Biopharmaceuticals, Inc. Announces New Analysis of Patient-Report Outcomes Data from the Promise-2 Phase 3 Clinical Trial of Eptinezumab	19-05-08	CI
Alder BioPharmaceuticals, Inc. Presents New Analysis of Patient-Reported Outcomes Following Eptinezumab Treatment for Migraine Prevention	19-05-08	CI
Alder BioPharmaceuticals Presents New Data Demonstrating Consistent, Early and Robust Prevention with Eptinezumab for Episodic and Chronic Migraine Across Four Clinical Trials	19-05-06	CI
Transcript : Alder BioPharmaceuticals, Inc., Q1 2019 Earnings Call, May 02, 2019	19-05-02
Alder Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-02	CI
Alder Biopharmaceuticals, Inc. Announces Resignation of Deepika R. Pakianathan as Class II Director	19-04-30	CI
Certain Stock Options of Alder BioPharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 29-APR-2019.	19-04-28	CI
Certain Restricted Stock Units of Alder BioPharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 29-APR-2019.	19-04-28	CI
Certain Class A-1 Convertible Preferred Stock of Alder BioPharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 29-APR-2019.	19-04-28	CI
Alder Biopharmaceuticals® to Present New Analyses of Eptinezumab’s Clinical Trial Data Describing Early, Robust Migraine Prevention and Quality of Life Impact at 2019 American Academy of Neurology Annual Meeting	19-04-23	CI

Chart Alder BioPharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-3.10%	102B
REGENERON PHARMACEUTICALS, INC.	+2.11%	96.07B
ARGENX SE	-1.80%	21.66B
BIONTECH SE	-17.75%	20.77B
GENMAB A/S	-6.91%	18.53B
WUXI APPTEC CO., LTD.	-42.00%	16.91B
BEIGENE, LTD.	-28.19%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.18%	13.33B
SAREPTA THERAPEUTICS, INC.	+19.90%	10.94B

Bio Therapeutic Drugs